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Background: Several studies have investigated the predictors of in-hospital mortality for COVID-19
patients who need to be admitted to the Intensive Care Unit (ICU). However, no data on the role of orga-
nizational issues on patients’ outcome are available in this setting. The aim of this study was therefore to
assess the role of surge capacity organisation on the outcome of critically ill COVID-19 patients admitted
to ICUs in Belgium.
Methods: We conducted a retrospective analysis of in-hospital mortality in Belgian ICU COVID-19
patients via the national surveillance database. Non-survivors at hospital discharge were compared to
survivors using multivariable mixed effects logistic regression analysis. Specific analyses including only
patients with invasive ventilation were performed. To assess surge capacity, data were merged with
administrative information on the type of hospital, the baseline number of recognized ICU beds, the
number of supplementary beds specifically created for COVID-19 ICU care and the “ICU overflow” (i.e.
a time-varying ratio between the number of occupied ICU beds by confirmed and suspected COVID-19
patients divided by the number of recognized ICU beds reserved for COVID-19 patients; ICU overflow
was present when this ratio is  1.0).
Findings: Over a total of 13,612 hospitalised COVID-19 patients with admission and discharge forms reg-
istered in the surveillance period (March, 1 to August, 9 2020), 1903 (14.0%) required ICU admission, of
whom 1747 had available outcome data. Non-survivors (n = 632, 36.1%) were older and had more fre-
quently various comorbid diseases than survivors. In the multivariable analysis, ICU overflow, together
with older age, presence of comorbidities, shorter delay between symptom onset and hospital admis-
sion, absence of hydroxychloroquine therapy and use of invasive mechanical ventilation and of ECMO,
was independently associated with an increased in-hospital mortality. Similar results were found in in
in the subgroup of invasively ventilated patients. In addition, the proportion of supplementary beds spe-
cifically created for COVID-19 ICU care to the previously existing total number of ICU beds was associ-
ated with increased in-hospital mortality among invasively ventilated patients. The model also indicated
a significant between-hospital difference in in-hospital mortality, not explained by the available patients
and hospital characteristics.
Interpretation: Surge capacity organisation as reflected by ICU overflow or the creation of COVID-19 specific
supplementary ICU beds were found to negatively impact ICU patient outcomes.
Funding: No funding source was available for this study.
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Evidence before this study
Mortality among critically ill patients with COVID-19 admitted
to intensive care units (ICU) varies significantly across coun-
tries. We searched PubMed, Science Citation Index, the
Cochrane Injuries Group and Embase for all publications until
October 15, 2020 and found several cohort studies reporting
relevant clinical and biological variables that can significantly
predict in-hospital mortality in this patients’ population, such
as age, immunosuppression, renal injury, the use of invasive
mechanical ventilation or elevated D-dimers levels. However,
there are no available data on the role of organizational charac-
teristics as risk factor associated with in-hospital mortality
among ICU COVID-19 patients. As such, we considered to assess
the prognostic role of several organizational characteristics
using the Belgian clinical surveillance database for COVID-19
patients requiring ICU admission.
Added value of this study
Our cohort study included 1747 critically ill patients admitted
to Belgian ICUs with complete discharge data on August 9,
2020; overall hospital mortality rate was 36.1%. In the multivar-
iable model, ICU overflow (i.e. the ratio between the number of
occupied ICU beds by confirmed and suspected COVID-19
patients divided by the number of recognized ICU beds
reserved for COVID-19 patients) was independently associated
with in-hospital mortality in the overall cohort. A high propor-
tion of supplementary beds specifically created for COVID-19
ICU care was a risk factor for in-hospital mortality in patients
undergoing invasive mechanical ventilation (n=999). In this
subpopulation, the effect of overflow remains similar, although
not statistically significant.
Implications of all the available evidence
This study found that ICU overflow and a high number of newly
created ICU beds might significantly influence the outcome of
critically ill patients with COVID-19. Management of the
COVID-19 crisis should take these factors into account to orga-
nize ICU admissions.1. Introduction
Since the rapid spread of the novel severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), critical care physicians have
faced an increasing number of patients suffering from an acute hyp-
oxemic respiratory failure associated with coronavirus disease 2019
(COVID-19) [1]. Many of these patients required the use of invasive
mechanical ventilation (IMV), which was associated with a mortality
rate between 40 and 65% [1,2]. Therapeutic interventions have there-
fore focused not only on reversing hypoxaemia and providing ade-
quate organ support but also on potential treatments to decrease the
viral load or the burden of the inflammatory response, thus limiting
disease severity [3].
Understanding the outcome and the risk-factors for in-hospital
mortality of COVID-19 patients admitted to the intensive care units
(ICUs) remains a complex issue. In a large cohort of 1591 ICU patients
in the area of Lombardy, 99% of them required respiratory support
(i.e. mostly IMV) and ICU mortality was 26% [4]; however, study
interpretation was flawed because 58% of patients were not yetPlease cite this article as: F.S. Taccone et al., The role of organizational cha
in Belgium, The Lancet Regional Health - Europe (2020), https://doi.org/1discharged at the moment of data analysis. Another study described
a cohort of 257 adult COVID-19 patients admitted to the ICUs in New
York [5]; IMV and renal replacement therapy were used in 79% and
31% of patients, respectively. Overall mortality was 39%, although 94
(37%) patients were still hospitalised. A more recent study showed
that among 5062 COVID-19 patients admitted to the ICU in England,
1547 (31%) deaths were reported, with significant between-centres
differences [6].
From March 1 up to August 9, 2020, a total of 73,401 people have
been tested positive for SARS-CoV-2 in Belgium, leading to 9746
deaths. Mortality was high among nursing home residents, who
accounted for half of all reported deaths, although most of cases were
suspected only on clinical symptoms. Overall in-hospital death
occurred in 21% of admitted patients [7]. Considering the variable
need for available ICU beds and resources for critically ill patients,
some studies have focused on predictors of hospital mortality to bet-
ter help clinicians to readdress the intensity of care and to better
understand optimal patient management [8,9]. However, none of
those evaluated whether factors related to surge capacity organisa-
tion, such as baseline number of recognized ICU beds, ICU overflow
and creation of supplementary COVID-19 specific ICU beds, might
also influence the outcome of these patients significantly. Indeed,
this information is of utmost importance for health authorities in
order to address future outbreaks and organise ICU capacity.
The aim of this study was to analyse clinical characteristics, use of
resources and predictors of mortality of critically ill patients admitted
to Belgian ICUs with COVID-19, with a particular focus on ICU organi-
zational characteristics.2. Methods
2.1. Study Design
This study was based on the national clinical surveillance of hospi-
talized patients with COVID-19 implemented by Sciensano, the Bel-
gian Institute of Health, and supported by the Federal Health
Ministry, in order to obtain a minimal health-related dataset for
patients diagnosed with COVID-19 admitted to Belgian hospitals.
Details on the surveillance program have been published [10]. The
clinical surveillance program was applied to all Belgian hospitals/
ICUs; nearly 72% of them contributed to the data collection [10].
Available ICU beds in Belgium before pandemics were 2000 (i.e. of
those, 1200 were reserved for COVID-19 patients); a total of 800
additional ICU beds were created during the surge, with a total of
2000 ICU beds reserved for COVID-19 patients.
For this study, all patients with a SARS-CoV-2 infection admit-
ted to one of the Belgian ICUs from March 1, 2020 up to August
9, 2020 and with registered admission and discharge forms were
eligible. SARS-CoV-2 infection was confirmed by: a) a positive
result of real-time reverse transcriptase-polymerase chain reac-
tion assay of nasopharyngeal swabs or bronchoalveolar lavage or
b) a rapid antigen tests (criteria included since the 3rd of April) or
c) chest computed tomography (CT) scan showing suggestive
signs of COVID-19 infection, according to local radiological
reports (criteria included since the 3rd of April). Patients who
were transferred to another hospital and/or with unknown status
at hospital discharge were excluded from the final analysis. The
hospital data collection was done by Sciensano, which is legally
entitled for surveillance of infectious diseases in Belgium (Royal
Decree of 21/03/2018). The COVID-19 clinical surveillance was
authorized by the independent administrative authority protect-
ing privacy and personal data, and Ethical approval was obtained
from the ethical committee of Ghent University Hospital (BC-
07507), which waived the informed consent because of the anon-
ymous and retrospective data analysis.racteristics on the outcome of COVID-19 patients admitted to the ICU
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Clinical data reported in this study were collected from Belgian gen-
eral hospitals through two online secured questionnaires in LimeSurvey
filled in by hospital staff and directly saved on the central server of Scien-
sano. The first questionnaire was filled after admission, the second after
hospital discharge or death, whichever came first. The recorded data
includes demographics, method of diagnosis, delay from symptoms to
hospital admission, clinical presentation at hospital admission, the use of
specific therapies during the hospital/ICU stay (i.e. hydroxychloroquine,
remdesivir, lopinavir/ritonavir, tocilizumab, macrolides, corticosteroids),
the use of IMV or extra-corporeal membrane oxygenation (ECMO), some
biological parameters on ICU admission (i.e. arterial partial pressure of
oxygen, PaO2; arterial partial pressure of carbon dioxide, PaCO2; pH; arte-
rial lactate; serum creatinine; total lymphocytes count; lactate dehydro-
genase, LDH; C-reactive protein, CRP), the occurrence of a secondary
infection of any origin, as well as ICU and hospital length of stay and in-
hospital mortality.
2.3. Organizational characteristics
To assess organizational characteristics, the data of the clinical sur-
veillance was merged based on the name of the hospital with adminis-
trative information on: a) the type of hospital (i.e. university hospital;
general hospital with university characteristics; general hospital) b) the
baseline number of recognized ICU beds; c) the creation of supplemen-
tary ICU beds specifically for COVID-19 care, expressed as the proportion
of created beds among the total (created and recognized) ICU beds; d)
“ICU overflow”, defined as the dynamic ratio between the number of
occupied ICU beds by confirmed and suspected COVID-19 patients
divided by the number of recognized ICU beds reserved for COVID-19
patients (i.e. 60% of the total number of recognized ICU beds). ICU over-
flow was calculated for each patient over an average of 8 days, the
median length of stay in ICU (among all ICU patients including patients
transferred out), starting from the date of ICU admission of the patient.
ICU overflow was categorized as “present” (i.e. ratio  1.0) or “absent”
(i.e. ratio< 1.0). The number of occupied ICU beds by confirmed and sus-
pected COVID-19 patients at a given day in a given hospital was derived
from the hospital Surge Capacity survey data collection [10].
2.4. Statistical analysis
Statistical analyses were performed using R software (R-version
3.6.0 and RStudio version 1.0.153). Descriptive statistics wereFig. 1. Flow-chart of the study: COVID-19 hospital clinica
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histograms and normal-quantile plots were examined to verify the
normality of distribution of continuous variables. Discrete variables
were expressed as counts (percentage) and continuous variables as
means§ SD or median [25th75th percentiles], as appropriate. Dem-
ographics and clinical differences between ICU survivors and non-
survivors were assessed using a chi-square, Fisher’s exact test, Stu-
dent’s t-test, or Mann-Whitney U test, as appropriate. The difference
in in-hospital mortality between different ranges of age for the whole
ICU cohort and only considering those patients undergoing IMV was
analysed using a chi-square test. Multivariable logistic regression
analysis with in-hospital mortality as the dependent variable was
performed including variables associated with in-hospital mortality
(p < 0.2) on a univariate basis. We calculated individual differences
for in-hospital mortality in each participating hospital by assuming
hospital-specific random intercepts. Additional analyses were per-
formed evaluating: a) only patients treated with IMV; b) only
patients with available biological data on ICU admission; c) a dataset
with tenfold multiple imputation for important prognostic baseline
covariates. Odds ratios (OR) with 95% confidence intervals (CIs) were
computed. A p < 0.05 was considered as statistically significant.
Details for Statistical analyses are available in the Supplemental
Material.2.5. Role of funding source
No funding source was available for this study.3. Results
3.1. Study population
Among a total of 17,791 COVID-19 patients requiring hospital
admission and recorded in the hospital clinical surveillance database
during the study period, 13,612 had both admission and discharge
data available. Of those, 1903 (14.0% - Fig. 1) were admitted to ICU.
There were 156 patients transferred to another hospital and/or with
an unknown vital status at hospital discharge, leaving a total of 1747
patients for the final analyses. There were no differences between
the study population (n = 1747) and the overall ICU population
(n = 1903) (Supplementary Table 1).
Median time from the onset of symptoms to hospital admission
and from hospital to ICU admission were 7 [410] days and 1 [04]l surveillance, Belgium, March 1st  August 9th 2020.
racteristics on the outcome of COVID-19 patients admitted to the ICU
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study population are shown in Table 1. Overall, 68.1% (1177/1728)
patients were male and the median age was 66 [5575] years. 655
(37.5%) patients were aged 71 years or older. Seventy-six percent of
patients had at least one pre-existing comorbidity; the most frequent
ones were arterial hypertension, cardiovascular disease and diabetes
mellitus; 499 (30.6%) patients were on chronic therapy with angio-
tensin-converting enzyme (ACE) and/or angiotensin-II inhibitors.
The most frequent symptoms on admission were fever, dyspnoea
and cough; PaO2 on ICU admission was 68 [5683] mmHg, PaCO2 36
[3141] mmHg and pH 7.46 [7.407.49]. Other biological variables
are reported in Table 1. Invasive mechanical ventilation was used in
999/1692 (59.0%) patients; the proportion of patients treated with
IMV was significantly higher in patients between 51 and 70 years of
age when compared to others (Supplemental Figure 1; p < 0.001).
ECMO was implemented in 63/1671 (3.8%) patients. Secondary infec-
tions were diagnosed in 664/1313 (50.6%) patients. Most of patients
were treated with hydroxychloroquine (1308/1742, 75.1%), while a
few of them received other therapies (Table 1). ICU and hospital
length of stay were 9 [419] and 17 [1031] days, respectively; ICU
length of stay was significantly longer in patients on IMV (16 [826]
days) and on ECMO (20 [1035] days) than in others (4 [27] days;
p < 0.001).
3.2. Characteristics of survivors and non-survivors
Overall mortality was 36.1%; the median time from hospital
admission to death was 13 [724] days. In univariate analysis, non-
survivors were older and had more frequently previous cardiovascu-
lar disease, a history of arterial hypertension, pre-existing pulmonary
and chronic renal diseases than survivors (Table 1). In-hospital mor-
tality progressively increased by age in all ICU patients and in
patients treated with IMV (Supplemental Figure 2). There were fewer
healthcare workers and more nursing home residents among non-
survivors than survivors. Time from the onset of symptoms to hospi-
tal admission, but not from hospitalisation to ICU admission, was
shorter in non-survivors than survivors. On ICU admission, non-sur-
vivors more frequently presented with mental confusion or coma
compared to survivors. All available biological variables were signifi-
cantly different between non-survivors and survivors on ICU admis-
sion. Non-survivors were also more frequently treated with IMV and
ECMO, more frequently developed secondary infections and less fre-
quently received hydroxychloroquine than survivors.
3.3. Predictors of in-hospital mortality
In the multivariable mixed effects analysis, older age (OR 2.59
[95% CIs 2.223.01] per 10 years increase), the presence of chronic
pulmonary disease (OR 2.02 [1.382.96]), chronic renal disease (OR
2.14 [1.393.29]) or chronic immunosuppression (OR 2.74
[1.096.90]) and the absence of history of arterial hypertension (OR
0.67 [0.500.90]) were independently associated with in-hospital
mortality (Fig. 2). A shorter delay between symptom onset and hospi-
tal admission (0.97 [0.960.99]), IMV (7.40 [5.2210.50]) and ECMO
(8.83 [4.5017.34]) were also predictors of in-hospital mortality.
Treatment with hydroxychloroquine was associated with a lower in-
hospital mortality (0.64 [0.45-0.92]).
Although there was a significantly lower in-hospital mortality for
patients admitted to university hospital (77/273, 28.2%) when com-
pared to the others (general: 396/1086, 36.4% - general with univer-
sity characteristics: 157/381, 41.2% - p = 0.003), this effect
disappeared when accounting for the clustering effect within hospi-
tals. When taking into account all other covariates, the number of
recognized ICU beds remained negatively associated with in-hospital
mortality (Supplemental Figure 3; p = 0.03), while the ratio between
newly created ICU beds on the total number of ICU beds wasPlease cite this article as: F.S. Taccone et al., The role of organizational cha
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3; p = 0.002). Nevertheless, the significant association disappeared
for both variables when taking into account the individual hospital as
a random effect in the model (Supplemental Figure 3). The only orga-
nizational characteristic, which was independently associated with
in-hospital mortality, was ICU overflow (OR 1.42 [1.031.95]). The
adjusted probability of in-hospital mortality was 21% in the absence
of ICU overflow, while it rises to 27% when ICU overflow is present,
holding all other variables constant (Fig. 3). There was a significant
variation in hospital mortality of COVID-19 patients admitted to ICU
among different hospitals, when taking into account potential con-
founding variables (Fig. 4; p < 0.001). In the multivariable model
(Supplemental Figure 4) including all patients but using imputation
for missing values, the same predictors of in-hospital mortality were
observed.
3.4. Predictors of in-hospital mortality in patients treated with
mechanical ventilation
In the multivariable model (Supplemental Figure 5; n = 999; over-
all in-hospital mortality 48.7% - Supplemental Table 2), older age,
chronic lung disease, chronic renal disease, and chronic immunosup-
pression were all associated with in-hospital mortality. Being a nurs-
ing home resident was also significantly associated with mortality.
Both hydroxychloroquine and macrolide therapies were associated
with a significantly lower in-hospital mortality. The proportion of
supplementary ICU beds specifically created for COVID-19 ICU care
among the total number of ICU beds was an independent risk factor
for in-hospital mortality in the mixed model, thus accounting for
individual hospital differences. The adjusted predicted probabilities
of in-hospital mortality according the proportion of created ICU beds
are presented in Fig. 5. Non-survivors were more frequently hospital-
ised in hospitals with ICU overflow compared to survivors (225/445,
50.5% vs. 203/486, 41.7%; OR 1.43 [1.101.84] - p = 0.008), although
no longer statistically significant in the multivariable analysis (1.39
[0.942.01]; p = 0.07).
3.5. Predictors of in-hospital mortality in patients with available
biological data on admission
In the multivariable model (Supplemental Figure 6; n = 823 in
total; 757 with available outcome data), older age, absence of history
of arterial hypertension, chronic renal disease, a shorter delay
between symptoms onset and hospital admission, the use of IMV or
ECMO as well as creatinine and CRP values on admission were inde-
pendent significant predictors of in-hospital mortality. Also, ICU
overflow was independently associated with in-hospital mortality.
Significant differences between the entire cohort and the subgroup of
patients with available biological data on ICU admission are shown in
Supplemental Table 3.
4. Discussion
In this study, we observed that hospital mortality in severe
COVID-19 patients requiring admission into Belgian ICUs was 36%. A
median of 38% of supplementary ICU beds specifically created for
COVID-19 ICU care above the total available beds was available in
Belgian ICUs during the COVID-19 pandemic. ICU organizational
characteristics, such as ICU overflow (all cohort) and a high propor-
tion of additionally created ICU beds (patients on IMV) were indepen-
dently associated with in-hospital mortality, together with older age,
comorbid diseases, a shorter time from the onset of symptoms to
hospital admission and the severity of respiratory impairment, which
was reflected by the use of IMV and ECMO. This study is the first sug-
gesting that mortality of critically ill COVID-19 patients could be
influenced by organizational factors that different health careracteristics on the outcome of COVID-19 patients admitted to the ICU
0.1016/j.lanepe.2020.100019
Table 1
Characteristics of ICU-patients with available status at discharge (n=1747) according to the in-hospital mortality. COVID-19 hospital clinical surveillance, Bel-
gium, March 1st  August 9th, 2020. Data are presented as count (percentage) or median [IQRs].
All patients (n=1747) Survivors (n=1115) Non-survivors (n=632) Missing p value
DEMOGRAPHICS
Age, years 66 [5575] 62 [5171] 73 [6479] - <0.001
<=30, n (%) 39 (2.2) 38 (3.4) 1 (0.1) - <0.001
31-40, n (%) 68 (3.9) 63 (5.6) 5 (0.8) - <0.001
41-50, n (%) 179 (10.2) 159 (14.2) 20 (3.1) - <0.001
51-60, n (%) 354 (20.3) 264 (23.6) 90 (14.2) - <0.001
61-70, n (%) 452 (25.9) 297 (26.6) 155 (24.5) - 0.36
71-80, n (%) 466 (26.7) 228 (20.4) 238 (37.6) - <0.001
>80, n (%) 189 (10.8) 66 (5.9) 123 (19.4) - <0.001
Male Gender, n (%) 1177 (68.1) 755 (68.1) 422 (68.1) 19 0.99
Pre-existing comorbidities
Cardiovascular Disease, n (%) 572 (32.7) 308 (27.6) 264 (41.7) - <0.001
History of arterial hypertension, n (%) 771 (44.1) 468 (41.9) 303 (47.9) - 0.02
Diabetes mellitus, n (%) 450 (25.8) 272 (24.3) 178 (28.1) - 0.09
Obesity (Body Mass Index > 30 Kg/m2), n (%) 207 (19.2) 139 (19.3) 68 (18.8) 667 0.91
Pre-existing pulmonary disease, n (%) 260 (14.9) 141 (12.6) 119 (18.8) - <0.001
Pre-existing neurological disease, n (%) 97 (5.6) 63 (5.6) 34 (5.3) - 0.89
Cognitive disorder, n (%) 71 (4.5) 41 (4.0) 30 (5.3) 158 0.28
Chronic renal disease, n (%) 190 (10.9) 79 (7.1) 111 (17.5) - <0.001
Chronic liver disease, n (%) 67 (3.8) 39 (3.4) 28 (4.4) - 0.39
Solid cancer, n (%) 108 (6.2) 61 (5.4) 47 (7.4) - 0.13
Hematological cancer, n (%) 39 (2.2) 21 (1.8) 18 (2.8) 103 0.25
Presence of immunosuppression, n (%) 48 (2.7) 24 (2.1) 24 (3.8) - 0.06
No comorbidities, n (%) 415 (23.8) 316 (28.3) 99 (15.6) - <0.001
Smoking, n (%) 103 (10.5) 57 (10.1) 31 (9.9) 11 0.99
ACEIs and/or ARBs, n (%) 499 (30.6) 306 (27.4) 193 (30.5) 15 0.19
Risk factors
Health-care worker, n (%) 51 (2.9) 43 (3.9) 8 (1.2) 13 0.002
Nursing home resident, n (%) 123 (7.1) 57 (5.1) 66 (10.4) 10 <0.001
Disease characteristics
Days from symptoms to hospital admission 5 [28] 6 [38] 4 [27] - <0.001
Diagnosis by RT-PCR, n (%) 1551 (89.0) 988 (88.6) 563 (89.1) - 0.82
Diagnosis by chest CT-scan, n (%) 630 (36.0) 421 (59.2) 209 (58.2) 1153 0.78
Diagnosis by rapid antigen method, n (%) 39 (2.0) 19 (2.7) 20 (5.6) 1103 0.02
Body temperature on admission,°C 37.6 [36.7-38.3] 37.6 [36.7-38.4] 37.6 [36.7-38.3] - 0.31
Weakness, n (%) 723 (41.4) 482 (43.2) 241 (38.1) - 0.04
Cough, n (%) 1032 (59.1) 697 (62.5) 335 (53.0) - <0.001
Throat pain, n (%) 111 (6.4) 86 (7.7) 25 (3.9) - 0.002
Rhinitis, n (%) 73 (4.2) 60 (5.4) 13 (2.0) - <0.001
Anosmia, n (%) 61 (3.9) 50 (5.0) 11 (2.0) 201 0.004
Dyspnea, n (%) 1131 (64.7) 717 (64.3) 414 (65.5) - 0.65
Diarrhea, n (%) 269 (15.4) 188 (16.8) 81 (12.8) - 0.03
Nausea/vomiting, n (%) 181 (10.4) 131 (11.7) 50 (7.9) - 0.01
Headache, n (%) 177 (10.1) 135 (12.1) 42 (6.6) - <0.001
Symptoms of mental illness, n (%) 102 (5.8) 53 (4.7) 49 (7.7) - 0.01
Coma, n (%) 28 (1.6) 10 (0.9) 18 (2.8) - 0.003
Convulsions, n (%) 5 (0.3) 5 (0.4) 0 (0) - 0.99
Pharyngitis, n (%) 42 (2.4) 24 (2.1) 18 (2.8) - 0.45
Conjunctivitis, n (%) 12 (0.7) 9 (0.9) 3 (0.4) - 0.55
Asymptomatic, n (%) 43 (2.5) 34 (3.0) 9 (1.4) - 0.04
No clinical signs, n (%) 126 (7.2) 83 (7.4) 43 (6.8) - 0.69
Abnormal pulmonary imaging, n (%) 1618 (93.6) 1019 (92.3) 599 (95.8) 19 0.006
Day from hospital to ICU admission 1 [04] 1 [04] 1 [03] - 0.28
Day from symptoms to ICU admission 7 [410] 8 [511] 7 [310] - <0.001
PaO2 on ICU admission, mmHg 68 [5683] 69 [5785] 66 [5481] 364 0.01
PaCO2 on ICU admission, mmHg 36 [3141] 36 [3140] 37 [3144] 363 0.004
pH on ICU admission 7.46 [7.407.49] 7.46 [7.427.49] 7.44 [7.357.48] 362 <0.001
Lactate on ICU admission, mmol/L 1.3 [0.92.0] 1.2 [0.81.8] 1.5 [1.12.5] 479 <0.001
Creatinine on ICU admission, mg/dL 1.03 [0.762.59] 0.92 [0.701.51] 1.38 [0.907.95] 537 <0.001
Lymphocytes on ICU admission, n/mm3 590 [231000] 740 [221108] 420 [14800] 666 <0.001
LDH on ICU admission, IU/L 477 [355624] 446 [334584] 542 [405700] 679 <0.001
CRP on ICU admission, mg/dL 150.4 [88244] 128 [71219] 176 [105-259] 513 <0.001
Therapies and complications
Mechanical ventilation, n (%) 999 (57.1) 512 (47.1) 487 (80.5) 55 <0.001
Age <=30, n (%) 9 (23.1) 8 (21.0) 1 (100) 0.23
Age 31-40, n (%) 22 (33.8) 18 (29.5) 4 (100) 0.01
Age 41-50, n (%) 84 (47.5) 66 (41.7) 18 (94.7) <0.001
Age 51-60, n (%) 220 (51.3) 134 (52.5) 86 (49.4) <0.001
Age 61-70, n (%) 286 (64.7) 150 (51.7) 136 (89.4) <0.001
Age 71-80, n (%) 296 (66.4) 121 (55) 175 (77.4) <0.001
Age >80, n (%) 82 (45.6) 15 (23.1) 67 (58.2) <0.001
ECMO, n (%) 63 (3.6) 21 (1.9) 42 (7.1) 108 <0.001
Secondary Infection, n (%) 664 (38.0) 374 (46.5) 290 (71.4) 27 <0.001
(continued)
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Table 1 (Continued)
All patients (n=1747) Survivors (n=1115) Non-survivors (n=632) Missing p value
Hydroxychloroquine, n (%) 1308 (74.8) 859 (77.1) 449 (71.4) 7 0.01
Lopinavir/Ritonavir, n (%) 18 (1.0) 9 (0.9) 9 (1.4) 7 0.22
Remdesivir, n (%) 18 (1.0) 15 (1.3) 3 (0.4) 9 0.13
Tocilizumab, n (%) 36 (2.0) 25 (2.2) 11 (1.7) 11 0.59
Macrolides, n (%) 247 (14.1) 167 (15.2) 80 (12.7) 7 0.08
Corticosteroids, n (%) 332 (21.7) 204 (20.5) 128 (24.0) 198 0.13
Outcomes
ICU length of stay, days 9 [419] 9 [420] 9 [518] - 0.01
Hospital length of stay, days 17 [1031] 20 [1236] 13 [724] - <0.001
Organizational issues
General Hospital, n (%) 1086 (62.4) 690 (62.1) 396 (62.8) 6 0.81
General Hospital with University Characteristics, n (%) 381 (21.8) 224 (20.1) 157 (24.9) 6 0.02
University Hospital, n (%) 273 (15.6) 196 (17.7) 77 (12.2) 6 0.003
Number of recognized ICU beds 22 [1336] 22 [1336] 22 [1439] 8 0.84
Proportion between created and total ICU beds 0.38 [0.300.48] 0.38 [0.290.49] 0.38 [0.300.47] 8 0.27
ICU overflow, n (%) 745 (46.1) 460 (44.1) 285 (49.7) 88 0.03
ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; CRRT = continuous renal replacement therapy; ACEIs = angiotensin converting
enzyme inhibitors; ARBs = angiotensin II receptor blockers;
* = with low molecular weight heparins on ICU admission
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creation of additional beds and the challenges of local overflow,
sometimes exceeding trained available ICU staffing and resource
capacity.
The severity of cases and the rapidly overwhelming caseload dur-
ing the COVID-19 pandemic spread has made ICUs worldwide suffer
from physical, material and emotional exhaustion [11]. The high
number of expected hypoxemic patients requiring ICU admission
was an unseen organisational challenge, related to the availability of
ICU beds and ventilators to manage the peak surge. In most countries,
huge efforts had to be made to make sufficient ICU beds available by
reducing or cancelling scheduled or non-urgent admissions, but also
to turn hospital wards, recovery rooms, operating theatres and emer-
gency rooms into novel ICUs [12]. A major bottleneck to this opera-
tional health care changes was the availability of adequately trained
ICU personnel. This led to physical exhaustion and a high incidence
of severe psychological burnout amongst ICU doctors, nurses, and
physiotherapists [13].Fig. 2. Multivariable mixed-effects model for predictors of in-hospital mortality (fixed effec
Belgium, March 1st  August 9th 2020. The following fixed effects were retained in the final
nary disease, arterial hypertension, days from symptoms to hospital admission, extra-corp
was added as a random effect to the model. Odds ratio per 10 years of age is shown. Abbre
IMV = invasive mechanical ventilation; ImmS = chronic immunosuppression; CRenD = chron
Please cite this article as: F.S. Taccone et al., The role of organizational cha
in Belgium, The Lancet Regional Health - Europe (2020), https://doi.org/1Concomitantly, to avoid rationing of critical care services, physi-
cians and nurses from other departments had to be deployed in the
ICU, often in a so-called “tiered staffing model”, which integrated
experienced ICU personnel with reassigned hospital staff members
(i.e. from operating rooms, internal medicine or other wards).
Although this model was the only feasible solution in this urgent situ-
ation, no data on the impact on the quality of critical care provided to
COVID-19 patients, the occurrence of avoidable errors (i.e. drug prep-
arations, weaning protocols, response to critical alarms), the ade-
quate supervision to the tiered staff and the sufficient training of
non-ICU personnel have been reported. Our results suggest that the
COVID-19 pandemic has revealed the vulnerability of the organisa-
tion of the ICU healthcare system and that readdressing critically ill
patients to other specialized ICUs (i.e. in the same country or towards
closer international centres) might be more beneficial for patients
than creating new ICU beds or taking care of a very high number of
critically ill COVID-19 patients, that exceeds the usual ICU flow out-
side the pandemic. Collaboration with other hospitals withints) among COVID-19 patients admitted to ICU. COVID-19 hospital clinical surveillance,
model: age, gender, chronic immunosuppression, chronic renal disease, chronic pulmo-
oreal membrane oxygenation, invasive mechanical ventilation, and overflow. Hospital
vations: HCQ = hydroxychloroquine; ECMO = extra-corporeal membrane oxygenation;
ic renal disease; CPulmD = chronic pulmonary disease; HTN = arterial hypertension.
racteristics on the outcome of COVID-19 patients admitted to the ICU
0.1016/j.lanepe.2020.100019
Fig. 3. Adjusted predicted values of mortality for overflow. COVID-19 hospital clinical
surveillance, Belgium, March 1st  August 9th 2020. The marginal effect of overflow is
based on a mixed effects model with a random effect for each hospital and fixed effects
for age, gender, chronic immunosuppression, chronic renal disease, chronic pulmonary
disease, arterial hypertension, days from symptoms to hospital admission, hydroxy-
chloroquine, extra-corporeal membrane oxygenation, invasive mechanical ventilation,
and overflow. Means are used to fix continuous variables and proportions are used to
fix categorical variables.
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organizations) can be helpful to ensure allocation of patients in ICUs
with adequate supplies, materials and available trained personnelFig. 4. Between hospital variation in in-hospital mortality among COVID-19 patients admit
fixed effects for age, gender, chronic immunosuppression, chronic renal disease, chronic p
hydroxychloroquine, extra-corporeal membrane oxygenation, invasive mechanical ventilati
9th 2020. In red, hospitals with higher adjusted in-hospital mortality; in blue, hospitals with
global estimate for the intercept).
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characteristics (i.e. number of ICU physicians and specialized nurses)
and of valuable studies from Belgium analyzing inter-hospital vari-
ability in mortality or other outcomes limits the validity on this
hypothesis to explain our observation.
Whether these data might also explain the potential relationship
between higher in-hospital mortality and a lower number of avail-
able ICU beds per 100,000 population (i.e. more ICU overflow and
higher number of newly created ICU beds) observed across different
European countries needs to be further explored. In this setting, Bel-
gium has one of the highest number of ICU beds per capita in Europe,
with 16 beds per 100,000 inhabitants [14]. Within the subgroup anal-
ysis of patients that underwent IMV, the proportion of newly created
ICU beds compared to previously existing ICU beds was an indepen-
dent risk factor for mortality. This variable is likely a proxy for ICU
staff qualification as smaller, less experienced centres had to create
more beds to adapt to the pandemic surge. The ICU overflow variable
became borderline non-significant in this subgroup likely due to
decreased cohort size and statistical power.
In this study, clinical predictors of in-hospital mortality were simi-
lar to those shown in other reports. Mortality for COVID-19 patients
who received IMV often exceeded 50% in several series [15,16].
Whether the use of mechanical ventilation is just the marker of lung
impairment severity due to viral spread or is a determinant of poor
outcome, remains poorly evaluated. In COVID-19 patients, the goal of
using IMV is to save lives from severe and refractory hypoxemia,
gaining time to allow lung healing. Unfortunately, data about the use
of non-invasive mechanical ventilation or on respiratory function
and related therapies (i.e. ventilatory parameters or modes, static
compliance or driving pressure,), which can also impact patient out-
comes, were lacking in this database for further adjustments
[8,1719]. Although a recent study reported a 60-day mortalityted to ICU, based on a mixed effects model with a random effect for each hospital and
ulmonary disease, arterial hypertension, days from symptoms to hospital admission,
on, and overflow. COVID-19 hospital clinical surveillance, Belgium, March 1st  August
lower adjusted in-hospital mortality compared to the average over all hospitals (i.e. the
racteristics on the outcome of COVID-19 patients admitted to the ICU
0.1016/j.lanepe.2020.100019
Fig. 5. Adjusted predicted values of mortality for the proportion of created ICU beds in ventilated patients. COVID-19 hospital clinical surveillance, Belgium, March 1st  August 9th
2020. The marginal effect of the proportion of created ICU beds is based on a mixed effects model with a random effect for each hospital and fixed effects for age, gender, chronic
immunosuppression, chronic renal disease, chronic pulmonary disease, arterial hypertension, days from symptoms to hospital admission, hydroxychloroquine, macrolides, extra-
corporeal membrane oxygenation, invasive mechanical ventilation, nursing home resident, and the proportion of created ICU beds. Means are used to fix continuous variables and
proportions are used to fix categorical variables.
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in our study hospital mortality associated with the use of ECMO was
66%; whether this result is related to patients’ selection, the lack of
recognized ECMO centres in Belgium or the development of ECMO-
related complications, is impossible to analyse from the available ret-
rospective data. Ongoing analyses of large registries would further
clarify the role of ECMO support in COVID-19 patients. Several other
studies have reported older age and the presence of several comorbid
diseases as independent predictors of poor outcome [8,18,21]. Inter-
estingly, another study also reported that a shorter median time from
disease onset to ICU admission, in particular when it was shorter
than one week, was associated with a higher in-hospital mortality
[22]; these findings are probably related to a more rapid and severe
progression of the disease, as suggested by a higher number of con-
comitant failing organs and had higher IL-6 levels. Although arterial
hypertension was more common among non-survivors in the univar-
iate analysis, it was found as a protective factor for mortality in the
multivariate analysis. This could be because it was a proxy for
patients that were not in shock as these patients may less likely be
classified as having hypertension.
Another important finding is the between-centres variability in
hospital mortality; this has been already reported in ICUs from
United Kingdom [6], while the cause of such findings remains unclear
and may have a variety of explanations, including local practices, ICU
staff expertise, use of resources and unmeasured differences in
patients’ cohorts. Such results may however influence the optimal
decisional process to admit severe COVID-19 patients, who could be
transferred to more experienced and effective ICUs, or eventually
promote telemedicine to share protocols and practices among differ-
ent centres.
Lastly, very few studies have shown effectiveness of therapeutic
interventions in severe COVID-19 patients. Some therapies, such as
remdesivir or tocilizumab, which might have some effects on the
recovery of viral symptoms or reduced inflammation in adults hospi-
talized COVID-19 patients [23,24]. were rarely used in Belgium. Only
the use of corticosteroids has been shown to effectively reducePlease cite this article as: F.S. Taccone et al., The role of organizational cha
in Belgium, The Lancet Regional Health - Europe (2020), https://doi.org/1mortality in COVID-19 patients, in particular for patients receiving
oxygen therapy or treated with invasive mechanical ventilation [25].
In our study, mortality of ICU patients on steroids was 38% and the
proportion of patients treated with steroids was similar between sur-
vivors and non-survivors. However, corticosteroid use for critically ill
patients with COVID-19 was only recommended in Belgium after the
results of randomized trials were published (i.e. mid-June 2020).
Moreover, administration of these drugs could have been decided in
a later phase of the disease in some patients, data on the type and
daily dosages were not available, and some of these patients might
have been categorized as receiving corticosteroids when they were
receiving intravenous hydrocortisone for persistent hypotension
requiring vasopressors; this would be associated with a higher risk of
death and attenuate its impact in the statistical model. Treatment
with hydroxychloroquine was associated with a lower risk of in-hos-
pital mortality, in line with a previous analysis of the same observa-
tional Belgian surveillance data focusing on all hospitalized COVID-
19 patients [26]. Despite encouraging results on the reduction of viral
load and overall mortality observed in retrospective analyses [27],
recent randomized trials, with inherently higher methodological
quality, reported no significant effects on COVID-19 patient outcomes
and a recent systematic review suggested as significant increase in
mortality when combination of hydroxychloroquine and azithromy-
cin was used [28,29]. Our data should be therefore interpreted with
caution. Considering the context of previously published randomized
trials and the observational nature of this study, our results likely
reflect that less severely ill patients receive hydroxychloroquine.
This study has several limitations to acknowledge. First, the qual-
ity of reporting to a newly COVID-19 national hospital registration
system can be challenged. Second, data collection was not developed
to obtain specific ICU data (i.e. severity scores; organ failure; use of
vasopressors or dialysis); some of these factors are significant deter-
minants of patients’ outcome [6]. Also, there was some missing val-
ues, although the sensitivity analysis with imputation confirmed the
main results of the study. Third, it was impossible to compare
patients admitted to ''recognized ICU beds'' to those admitted toracteristics on the outcome of COVID-19 patients admitted to the ICU
0.1016/j.lanepe.2020.100019
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over the ''newly created ICU based'' could have been created in differ-
ent areas of the hospital (i.e. ward, operating room, previously
unavailable ICU beds). Also, no information on the type of available
“life-support therapies” (i.e. renal replacement therapy or ECMO)
were available; however, all ICU beds would have a ventilator and
ECMO use is available only in dedicated centers, as in other European
countries. We also missed information about the nurse to patients
ratio, which is 2:1 to 3:1 in Belgian ICUs; it remains therefore
unknown whether this ratio has significantly changed, as local nurs-
ing teams might have been integrated with non-ICU nurses, shifts
might have been changed according to local policies (i.e. 8 vs.
12 hours) and the exact number of available nurses could be different
on a daily basis. Similarly, the ICU physician to patients ratio could
have been different among ICUs and, as the nurse to patient ratio,
influence overall outcome. Importantly, no specific information on
triage for admission to recognized versus newly created ICU beds
was available into the registry. Forth, we could not assess the causes
of death, such as directly from COVID-19 infection, secondary compli-
cations, other events unrelated to the initial infection or withdrawal
of life sustaining treatment. Fifth, we evaluated outcome during hos-
pitalization (i.e. discharged alive vs. dead); prolonged follow-up
period (i.e. up to 90 days after admission) could have provided a
more reliable assessment of long-term outcome in these patients.
Finally, admission criteria to the ICU may differ from other countries,
which would limit the generalizability of our findings.5. Conclusions
In this national dataset with an hospital mortality of 36.1% for
COVID-19 patients requiring ICU admission, mortality varied signifi-
cantly across different centres and was associated with organiza-
tional characteristics, in particular ICU overflow and the proportion
of additionally created ICU beds. Management of crisis surges during
the following waves of COVID-19 and possible other pandemics
should take into account these factors to readdress patients into ICUs
with the adequate quality of care and available materials and trained
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